No connection

Search Results

BDRX vs HCTI

BDRX
Biodexa Pharmaceuticals Plc
BEARISH
Price
$2.15
Market Cap
$1.8M
Sector
Healthcare
AI Confidence
95%
HCTI
Healthcare Triangle, Inc.
BEARISH
Price
$2.40
Market Cap
$2.8M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BDRX
--
HCTI
--
Forward P/E
BDRX
--
HCTI
-0.08
P/B Ratio
BDRX
0.09
HCTI
0.14
P/S Ratio
BDRX
--
HCTI
0.21
EV/EBITDA
BDRX
-15012.8
HCTI
-1.29

Profitability

Gross Margin
BDRX
0.0%
HCTI
13.12%
Operating Margin
BDRX
0.0%
HCTI
-74.26%
Profit Margin
BDRX
0.0%
HCTI
-48.84%
ROE
BDRX
-61.77%
HCTI
-183.0%
ROA
BDRX
-39.04%
HCTI
-39.27%

Growth

Revenue Growth
BDRX
--
HCTI
44.6%
Earnings Growth
BDRX
--
HCTI
--

Financial Health

Debt/Equity
BDRX
0.04
HCTI
0.18
Current Ratio
BDRX
3.63
HCTI
2.03
Quick Ratio
BDRX
3.63
HCTI
1.94

Dividends

Dividend Yield
BDRX
--
HCTI
--
Payout Ratio
BDRX
0.0%
HCTI
0.0%

AI Verdict

BDRX BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of 2/9, indicating severe operational and financial distress. Despite a strong current and quick ratio suggesting short-term liquidity, the company is unprofitable across all margins, with deeply negative ROE and ROA. Valuation metrics are largely undefined due to lack of earnings and revenue data, while the stock has lost nearly all value over the past year. Insider sentiment is neutral-to-weak, and there is no analyst coverage or dividend support, amplifying risk.

Strengths
Strong liquidity position with current and quick ratios of 3.63, indicating ability to cover short-term liabilities.
Low debt/equity ratio of 0.04, reflecting minimal leverage risk.
Two out of three recent quarters beat earnings estimates, showing some operational predictability.
Risks
Piotroski F-Score of 2/9 indicates very weak financial health and high risk of continued deterioration.
No Altman Z-Score available, but negative ROE (-61.77%) and ROA (-39.04%) suggest high bankruptcy risk.
Profitability metrics are entirely negative: 0% gross, operating, and profit margins.
HCTI BEARISH

HCTI presents a classic value trap scenario, characterized by a stable Piotroski F-Score of 4/9 but catastrophic price action and fundamental decay. While the company shows strong top-line revenue growth of 44.6%, it is coupled with a disastrous ROE of -183% and an operating margin of -74.26%. The extreme discrepancy between the 52-week high ($7470) and current price ($2.40) indicates a total collapse in investor confidence or a massive corporate restructuring. Despite low debt and a healthy current ratio, the lack of profitability and negative earnings surprises make this a high-risk speculative asset.

Strengths
Strong YoY revenue growth of 44.60%
Low Debt/Equity ratio of 0.18
Healthy liquidity with a Current Ratio of 2.03
Risks
Catastrophic price performance (-99.9% 1Y change)
Severe negative profitability (Profit Margin -48.84%)
Extreme equity erosion (ROE -183%)

Compare Another Pair

BDRX vs HCTI: Head-to-Head Comparison

This page compares Biodexa Pharmaceuticals Plc (BDRX) and Healthcare Triangle, Inc. (HCTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile